The Quantellect read.As of Nov 19, 2026, 7 active firms cover Humacyte Inc: 5 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $0.50 to $25.00 (about 50.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $5.63 sits 1041% above the current $0.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy571%
Neutral229%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.63
+1041.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $0.49 current
Highest Target$25.00
Average Target$5.63
Lowest Target$0.50
Detailed analyst forecasts for HUMA
Showing 1–6 of 6 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 5 of 7 active firms rate HUMA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HUMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.08 – $-0.05 · 2 analysts · -50% YoY
Next period, 2 analysts expect Humacyte Inc to earn $-0.07 a share (range $-0.08 – $-0.05), versus $-0.13 a year earlier. Full-year consensus is $-0.37, growing to $-0.25 the year after.
REVENUE · NEXT QUARTER
$2.3M
Range $1.2M – $3.4M · 2 analysts · +375% YoY
Revenue is expected to reach $2.3M (range $1.2M – $3.4M), +374.5% year-over-year. Full-year consensus is $4.0M, rising to $23.4M next year.
Top analysts covering Humacyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HUMA.
#1
Ryan Zimmerman
BTIG · Rank #212
Buy
$2.00+305.7% to target
Overall win rate
37%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$4.00+711.4% to target
Overall win rate
38%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #487
Buy
$1.00+102.8% to target
Overall win rate
36%
+ Follow
#4
Matt Miksic
Barclays · Rank #543
Buy
$1.50+204.3% to target
Overall win rate
27%
+ Follow
#5
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$25.00+4971.0% to target
Overall win rate
22%
+ Follow
HUMA stock forecast FAQ
What is HUMA's average 12-month price target?+
The 6 active firms with a live target average $5.63 for Humacyte Inc over the next 12 months, ranging from a $25.00 high to a $0.50 low, as of Nov 19, 2026.
Is HUMA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HUMA?+
The Street-high target is $25.00 (D. Boral Capital), and the Street-low is $0.50 (Barclays). The average of all 6 active-firm targets is $5.63.
How many active Wall Street firms cover HUMA?+
7 active firms have a recognized rating on Humacyte Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HUMA?+
Among analysts who currently cover HUMA, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Buy with a $2.00 target.
What is Humacyte Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.08 – $-0.05) across 2 analysts. Full-year EPS is projected at $-0.37, rising to $-0.25 the following year.
How much revenue is Humacyte Inc expected to report next quarter?+
Consensus revenue is $2.3M (range $1.2M – $3.4M). Full-year revenue is projected at $4.0M, growing to $23.4M next year.
Have analysts been upgrading or downgrading HUMA lately?+
As of Nov 19, 2026, 5 of 7 active firms rate HUMA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HUMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.